Sedentary, trained, and treated groups (with insulin, L-carnitine, and/or alpha-lipoic acid) showed scores near 0, suggesting the absence of histopathological anomalies (Figure 5)
This metabolic safety profile makes AOD-9604 potentially suitable for individuals with metabolic syndrome or diabetes risk factors who might not tolerate traditional growth hormone therapy, though medical supervision remains appropriate
In that work, co-immunoprecipitation analysis showed reduced binding between caveolin-1 and eNOS, an interaction normally responsible for limiting eNOS activity
CJC-1295 : Prolongs growth hormone release over time
Regular use of berberine individually may help those measures, which may result in a better overall management of PMOS. Here are some of the possible ways the supplement can help people who have PMOS